Multi-cancer early detection (MCED)
Multi-cancer early detection (MCED) screens asymptomatic, average-risk individuals from a single blood draw for molecular signals shared across dozens of cancer types — a population-screening scenario distinct from companion-therapy diagnostics.
How it works
This is a procurement category, not a named manufacturer's product. As a paid service, Bioecon finds suppliers for your task, agrees configuration and specification, and arranges supply; the price is on request. Bioecon may receive a fee from suppliers — this is disclosed and does not affect the portal's grades or lists.
Technology
Multi-cancer early detection (MCED) — Evidence, registration route, funding and suppliers are on the technology page.
A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL's Galleri (US), Exact Sciences' Cancerguard (US) and Freenome (US), …
Links
- Import and registration route
- CHEM — Minpromtorg (registration) / Rospotrebnadzor (notification of …
- Capabilities
- Testing & analytics
Related items
Other categories for this technology
Analytical & testing services · Laboratory & analytical instruments
In the same node
Base editing · Bioelectronics experiment kits · Bioluminescence & marine fluorescent proteins · Breath-based diagnostics (breathomics) · Companion diagnostics platforms · CRISPR diagnostics · CRISPR educational kits · CRISPR screening as a service · All →